Cargando…
Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line
The incidence of endometrial cancer (EC) has increased over the past years and mainly affects women above the age of 45 years. Metabolic diseases such as obesity and type II diabetes mellitus as well as associated conditions like polycystic ovary syndrome (PCOS), insulin resistance and hyperinsuline...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943011/ https://www.ncbi.nlm.nih.gov/pubmed/33690729 http://dx.doi.org/10.1371/journal.pone.0248103 |
_version_ | 1783662413803945984 |
---|---|
author | Lange, Carsten Machado Weber, Amanda Schmidt, Ronny Schroeder, Christoph Strowitzki, Thomas Germeyer, Ariane |
author_facet | Lange, Carsten Machado Weber, Amanda Schmidt, Ronny Schroeder, Christoph Strowitzki, Thomas Germeyer, Ariane |
author_sort | Lange, Carsten |
collection | PubMed |
description | The incidence of endometrial cancer (EC) has increased over the past years and mainly affects women above the age of 45 years. Metabolic diseases such as obesity and type II diabetes mellitus as well as associated conditions like polycystic ovary syndrome (PCOS), insulin resistance and hyperinsulinemia lead to elevated levels of circulating estrogens. Increased estrogen concentrations, in turn, further trigger the proliferation of endometrial cells and thus promote EC development and progression, especially in the absence of progesterone as seen in postmenopausal women. Elevated blood glucose levels in diabetic patients further contribute to the risk of EC development. Metformin is an insulin-sensitizing biguanide drug, commonly used in the treatment of type II diabetes mellitus, especially in obese patients. Besides its effects on glucose metabolism, metformin displayed anti-cancer effects in various cancer types, including EC. Direct anti-cancer effects of metformin target signaling pathways that are involved in cellular growth and proliferation, e.g. the AKT/PKB/mTOR pathway. Further proteins and pathways have been suggested as potential targets, but the underlying mechanism of action of metformin’s anti-cancer activity is still not completely understood. In the present study, the effects of metformin on protein expression were investigated in the human EC cell line HEC-1A using an affinity proteomic approach. Cells were treated with 0.5 mmol/L metformin over a period of 7 days and changes in the expression pattern of 1,300 different proteins were compared to the expression in untreated control cells as well as insulin-treated cells. Insulin treatment (100 ng/mL) was incorporated into the study in order to implement a model for insulin resistance and associated hyperinsulinemia, conditions that are often observed in obese and diabetic patients. Furthermore, the culture medium was supplemented with 10 nmol/L ß-estradiol (E2) during treatments to mimic increased estrogen levels, a common risk factor for EC development. Based on the most prominent and significant changes in expression, a set of 80 proteins was selected and subjected to a more detailed analysis. The data revealed that metformin and insulin targeted similar pathways in the present study and mostly acted on proteins related to proliferation, migration and tumor immune response. These pathways may be affected in a tumor-promoting as well as a tumor-suppressing way by either metformin treatment or insulin supplementation. The consequences for the cells resulting from the detected expression changes were discussed in detail for several proteins. The presented data helps identify potential targets affected by metformin treatment in EC and allows for a better understanding of the mechanism of action of the biguanide drug’s anti-cancer activity. However, further investigations are necessary to confirm the observations and conclusions drawn from the presented data after metformin administration, especially for proteins that were regulated in a favorable way, i.e. AKT3, CCND2, CD63, CD81, GFAP, IL5, IL17A, IRF4, PI3, and VTCN1. Further proteins might be of interest, where metformin counteracted unfavorable effects that have been induced by hyperinsulinemia. |
format | Online Article Text |
id | pubmed-7943011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-79430112021-03-19 Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line Lange, Carsten Machado Weber, Amanda Schmidt, Ronny Schroeder, Christoph Strowitzki, Thomas Germeyer, Ariane PLoS One Research Article The incidence of endometrial cancer (EC) has increased over the past years and mainly affects women above the age of 45 years. Metabolic diseases such as obesity and type II diabetes mellitus as well as associated conditions like polycystic ovary syndrome (PCOS), insulin resistance and hyperinsulinemia lead to elevated levels of circulating estrogens. Increased estrogen concentrations, in turn, further trigger the proliferation of endometrial cells and thus promote EC development and progression, especially in the absence of progesterone as seen in postmenopausal women. Elevated blood glucose levels in diabetic patients further contribute to the risk of EC development. Metformin is an insulin-sensitizing biguanide drug, commonly used in the treatment of type II diabetes mellitus, especially in obese patients. Besides its effects on glucose metabolism, metformin displayed anti-cancer effects in various cancer types, including EC. Direct anti-cancer effects of metformin target signaling pathways that are involved in cellular growth and proliferation, e.g. the AKT/PKB/mTOR pathway. Further proteins and pathways have been suggested as potential targets, but the underlying mechanism of action of metformin’s anti-cancer activity is still not completely understood. In the present study, the effects of metformin on protein expression were investigated in the human EC cell line HEC-1A using an affinity proteomic approach. Cells were treated with 0.5 mmol/L metformin over a period of 7 days and changes in the expression pattern of 1,300 different proteins were compared to the expression in untreated control cells as well as insulin-treated cells. Insulin treatment (100 ng/mL) was incorporated into the study in order to implement a model for insulin resistance and associated hyperinsulinemia, conditions that are often observed in obese and diabetic patients. Furthermore, the culture medium was supplemented with 10 nmol/L ß-estradiol (E2) during treatments to mimic increased estrogen levels, a common risk factor for EC development. Based on the most prominent and significant changes in expression, a set of 80 proteins was selected and subjected to a more detailed analysis. The data revealed that metformin and insulin targeted similar pathways in the present study and mostly acted on proteins related to proliferation, migration and tumor immune response. These pathways may be affected in a tumor-promoting as well as a tumor-suppressing way by either metformin treatment or insulin supplementation. The consequences for the cells resulting from the detected expression changes were discussed in detail for several proteins. The presented data helps identify potential targets affected by metformin treatment in EC and allows for a better understanding of the mechanism of action of the biguanide drug’s anti-cancer activity. However, further investigations are necessary to confirm the observations and conclusions drawn from the presented data after metformin administration, especially for proteins that were regulated in a favorable way, i.e. AKT3, CCND2, CD63, CD81, GFAP, IL5, IL17A, IRF4, PI3, and VTCN1. Further proteins might be of interest, where metformin counteracted unfavorable effects that have been induced by hyperinsulinemia. Public Library of Science 2021-03-09 /pmc/articles/PMC7943011/ /pubmed/33690729 http://dx.doi.org/10.1371/journal.pone.0248103 Text en © 2021 Lange et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Lange, Carsten Machado Weber, Amanda Schmidt, Ronny Schroeder, Christoph Strowitzki, Thomas Germeyer, Ariane Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line |
title | Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line |
title_full | Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line |
title_fullStr | Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line |
title_full_unstemmed | Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line |
title_short | Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line |
title_sort | changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943011/ https://www.ncbi.nlm.nih.gov/pubmed/33690729 http://dx.doi.org/10.1371/journal.pone.0248103 |
work_keys_str_mv | AT langecarsten changesinproteinexpressionduetometformintreatmentandhyperinsulinemiainahumanendometrialcancercellline AT machadoweberamanda changesinproteinexpressionduetometformintreatmentandhyperinsulinemiainahumanendometrialcancercellline AT schmidtronny changesinproteinexpressionduetometformintreatmentandhyperinsulinemiainahumanendometrialcancercellline AT schroederchristoph changesinproteinexpressionduetometformintreatmentandhyperinsulinemiainahumanendometrialcancercellline AT strowitzkithomas changesinproteinexpressionduetometformintreatmentandhyperinsulinemiainahumanendometrialcancercellline AT germeyerariane changesinproteinexpressionduetometformintreatmentandhyperinsulinemiainahumanendometrialcancercellline |